PMID- 26084665
OWN - NLM
STAT- MEDLINE
DCOM- 20160408
LR  - 20220419
IS  - 1535-1645 (Electronic)
IS  - 1523-3812 (Linking)
VI  - 17
IP  - 8
DP  - 2015 Aug
TI  - Management of adverse effects of mood stabilizers.
PG  - 603
LID - 10.1007/s11920-015-0603-z [doi]
AB  - Mood stabilizers such as lithium and anticonvulsants are still standard-of-care 
      for the acute and long-term treatment of bipolar disorder (BD). This systematic 
      review aimed to assess the prevalence of their adverse effects (AEs) and to 
      provide recommendations on their clinical management. We performed a systematic 
      research for studies reporting the prevalence of AEs with lithium, valproate, 
      lamotrigine, and carbamazepine/oxcarbazepine. Management recommendations were 
      then developed. Mood stabilizers have different tolerability profiles and are 
      eventually associated to cognitive, dermatological, endocrine, gastrointestinal, 
      immunological, metabolic, nephrogenic, neurologic, sexual, and teratogenic AEs. 
      Most of those can be transient or dose-related and can be managed by optimizing 
      drug doses to the lowest effective dose. Some rare AEs can be serious and 
      potentially lethal, and require abrupt discontinuation of medication. Integrated 
      medical attention is warranted for complex somatic AEs. Functional remediation 
      and psychoeducation may help to promote awareness on BD and better medication 
      management.
FAU - Murru, Andrea
AU  - Murru A
AD  - Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of 
      Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain, AMURRU@clinic.ub.es.
FAU - Popovic, Dina
AU  - Popovic D
FAU - Pacchiarotti, Isabella
AU  - Pacchiarotti I
FAU - Hidalgo, Diego
AU  - Hidalgo D
FAU - Leon-Caballero, Jordi
AU  - Leon-Caballero J
FAU - Vieta, Eduard
AU  - Vieta E
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Curr Psychiatry Rep
JT  - Current psychiatry reports
JID - 100888960
RN  - 0 (Anticonvulsants)
RN  - 0 (Antimanic Agents)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Lithium Compounds)
RN  - 0 (Triazines)
RN  - 33CM23913M (Carbamazepine)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - U3H27498KS (Lamotrigine)
RN  - VZI5B1W380 (Oxcarbazepine)
SB  - IM
MH  - Anticonvulsants/adverse effects
MH  - Antimanic Agents/administration & dosage/*adverse effects
MH  - Antipsychotic Agents/administration & dosage/*adverse effects
MH  - Bipolar Disorder/*drug therapy
MH  - Carbamazepine/adverse effects/analogs & derivatives
MH  - Disease Management
MH  - Humans
MH  - Lamotrigine
MH  - Lithium Compounds/adverse effects
MH  - Oxcarbazepine
MH  - Triazines/adverse effects
MH  - Valproic Acid/adverse effects
EDAT- 2015/06/19 06:00
MHDA- 2016/04/09 06:00
CRDT- 2015/06/19 06:00
PHST- 2015/06/19 06:00 [entrez]
PHST- 2015/06/19 06:00 [pubmed]
PHST- 2016/04/09 06:00 [medline]
AID - 10.1007/s11920-015-0603-z [doi]
PST - ppublish
SO  - Curr Psychiatry Rep. 2015 Aug;17(8):603. doi: 10.1007/s11920-015-0603-z.